| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | 17.8 | -10.1 |
| EPS (diluted, $ a share) | $-5.13 | $-19.73 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ADGM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Adagio Medical Holdings, Inc.: key numbers
- Share price
- $1.65Close, Nov 17
- Market cap
- $1.62M
- Shares outstanding
- 983.43KLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Adagio Medical Holdings, Inc.
All →Adagio Medical Holdings Financial Results
Adagio Medical reported Q3 2026 financial results, highlighting a net income of $17.8 million primarily driven by a $23.0 million gain from the change in fair value of warrant liabilities. The company also announced that its Board of Directors has initiated a formal process to explore strategic alternatives to maximize shareholder value while continuing clinical progress on its vCLAS Ultra System.
- Term
- Q3 2026
“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter.”
Todd Usen, Chief Executive Officer of Adagio Medical
“As the Board’s review of strategic alternatives continues, we have aligned our cost structure around these prioritized programs and remain focused on maximizing value for our shareholders.”
Todd Usen, Chief Executive Officer of Adagio Medical
Adagio Medical Holdings Other 8-K Filing
Adagio Medical Holdings, Inc. filed an amendment to its Articles of Incorporation or Bylaws (Item 5.03). This type of filing typically involves administrative changes to corporate governance or the company's fiscal year structure.
Adagio Medical Holdings Reverse Stock Split
Adagio Medical Holdings stockholders approved a proposal for a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-500. The final ratio will be determined by the Board of Directors at its discretion to consolidate outstanding shares.
Adagio Medical Holdings $776K Debt Financing
Adagio Medical Holdings reported that a holder of its 13% Senior Secured Convertible Notes converted $776,111 in aggregate principal into 4,978,869 shares of common stock. The conversion occurred at prices ranging from $0.1265 to $0.1618 per share following the company's election to lower the conversion price to an 'Alternate Conversion Price' through October 31, 2026. This transaction represents the settlement of existing debt obligations through equity issuance with no new cash proceeds received.
- Value
- $776K
Adagio Medical Holdings Other 8-K Filing
Adagio Medical Holdings has initiated a formal process to explore strategic alternatives, including a potential merger or sale, to maximize shareholder value. In connection with this review, the company is reducing its workforce by 58% (25 of 43 employees) and expects to incur $1.3 million in cash expenditures for severance and related costs. Additionally, the company is lowering the conversion price for its 13% Senior Secured Convertible Notes through October 31, 2026, to facilitate potential debt conversions.